By Cindy H. Dubin, Contributor
Drug Delivery Technology
July/August 2008

Compliance concerns have driven and continue to drive investment in new drug delivery technologies, and the transdermal patch is a prominent example of this impact. Since the FDA approved the first transdermal patch in 1981, it has grown into a $2-billion market in the US with 35 approved products, according to Adhesives Research, Inc., a drug delivery company based in Glen Rock, PA.

Click here to read the full text of this article.